A Single Arm, Phase II Study of Adjuvant Endocrine Therapy, Subcutaneous Pertuzumab, and Trastuzumab Fixed-Dose Combination for Patients with Anatomic Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer (ADEPT)

Breast